PX-12

别名: DB05448, 1-methyl propyl 2-imidazolyl disulfide

目录号：S7947 Purity: 99.99%

PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide)是一种有效的 thioredoxin-1 (Trx-1) 抑制剂，作用于 Trx-1 上 Cys73 的不可逆硫代烷基化。Phase 2。

PX-12 Chemical Structure

CAS: 141400-58-0

规格	价格	库存
10mM (1mL in DMSO)	810.81	现货
10mg	794.43	现货
50mg	3087.63	现货
200mg	7182.63	现货
更大包装有超大折扣
400-668-6834 info@selleck.cn

产品质控

批次：纯度： 99.99%

99.99

PX-12相关产品

相关化合物库	代谢化合物库抗癌代谢化合物库谷氨酰胺代谢化合物库糖代谢化合物库脂代谢化合物库	点击展开

细胞实验数据示例

细胞系	实验类型	给药浓度	孵育时间	活性描述	文献信息(PMID)
M21	Function assay	25 nM	16 hrs	Stimulation of nuclear translocation of thioredoxin-1 from cytosol in human M21 cells at 25 nM after 16 hrs by immunocytofluorescence	18617414
Raji	Function assay	5 to 10 uM	4 to 24 hrs	Induction of Trx mRNA expression in human Raji cells at 5 to 10 uM after 4 to 24 hrs by RT-PCR analysis	22128876
Raji	Function assay	10 to 20 uM	4 to 8 hrs	Induction of Trx protein expression in human Raji cells at 10 to 20 uM after 4 to 8 hrs by Western blot analysis	22128876
T84	Function assay		3 hrs	Inhibition of human recombinant thioredoxin-mediated TG2 activation expressed in T84 cells assessed as blockade of 5-biotinamidopentylamine incorporation after 3 hrs by fluorescence microscopic analysis, IC50=2.11μM	23327656
Ramos	Cytotoxicity assay		72 hrs	Cytotoxicity against human Ramos cells after 72 hrs by MTT assay, LD50=3.4μM	22128876
PancO2	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse PancO2 cells after 72 hrs by crystal violet staining, LD50=3.9μM	22128876
T24	Cytotoxicity assay		72 hrs	Cytotoxicity against human T24 cells after 72 hrs by crystal violet staining, LD50=4.6μM	22128876
B78	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse B78 cells after 72 hrs by crystal violet staining, LD50=5μM	22128876
CT26	Cytotoxicity assay		72 hrs	Cytotoxicity against wild type mouse CT26 cells after 72 hrs by crystal violet staining, LD50=5.2μM	22128876
K562	Cytotoxicity assay		72 hrs	Cytotoxicity against human K562 cells after 72 hrs by MTT assay, LD50=5.5μM	22128876
MCF7	Antiproliferative assay		48 hrs	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B method, GI50=8.3μM	18617414
M21	Antiproliferative assay		48 hrs	Antiproliferative activity against human M21 cells after 48 hrs by sulforhodamine B method, GI50=8.3μM	18617414
Raji	Cytotoxicity assay		72 hrs	Cytotoxicity against human Raji cells after 72 hrs by MTT assay, LD50=8.8μM	22128876
EMT6	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse EMT6 cells after 72 hrs by crystal violet staining, LD50=11.6μM	22128876
HT29	Antiproliferative assay		48 hrs	Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B method, GI50=25μM	18617414
MEF	Cytotoxicity assay			Cytotoxicity against mouse MEF cells, LD50=2.7μM	22128876
M21	Antiproliferative assay			Antiproliferative activity against human M21 cells, GI50=8.3μM	18502639
MCF7	Antiproliferative assay			Antiproliferative activity against human MCF7 cells, GI50=8.3μM	18502639
HT29	Antiproliferative assay			Antiproliferative activity against human HT29 cells, GI50=25μM	18502639
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
SJ-GBM2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
A673	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB-EBc1	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
Saos-2	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
RD	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	29435139
NB1643	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	29435139
SK-N-MC	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	29435139
LAN-5	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	29435139
TC32	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
MG 63 (6-TG R)	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	29435139
Rh41	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	29435139
点击查看更多细胞系数据

生物活性

产品描述

PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide)是一种有效的 thioredoxin-1 (Trx-1) 抑制剂，作用于 Trx-1 上 Cys73 的不可逆硫代烷基化。Phase 2。

靶点

Trx-1 ^[1]

体外研究(In Vitro)
体外研究活性	在MCF-7和HT-29细胞中，PX-12防止低氧(1% 氧气)诱导的HIF-1alpha蛋白增加，并降低HIF-1反式激活活性，VEGF形成，和诱导型一氧化氮合酶。PX-12也会抑制MCF-7和HT-29细胞的生长，IC50s分别为1.9 μM和2.9μM。^[1] PX-12也会通过Nrf2/PMF-1介导的增加抑制HIF-1α蛋白质水平。^[2]在A549细胞中，PX-12通过G2/M细胞周期阻滞，和Bax-介导的，ROS-依赖性细胞凋亡抑制细胞生长。^[3]在肝癌细胞中，PX-12与5-FU发挥协同作用，显著抑制致瘤性。^[4]
细胞实验	细胞系	MCF-7 和 HT-29 细胞
	浓度	~10 μM
	孵育时间	72 小时
	方法	细胞生长使用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐法测量。在空气或低氧(1% 氧气)条件下，细胞在一系列浓度的PX-12或pleurotin中暴露16小时。然后细胞在空气中用温的不含药物的培养基洗涤，再进行后面的72小时培育。

体内研究(In Vivo)
体内研究活性	在负荷MCF-7肿瘤异种移植物的小鼠中，PX-12 (12 mg/kg, i.p.)降低HIF-1α 与 VEGF蛋白质水平和微血管密度。^[1]
动物实验	Animal Models	负荷MCF-7肿瘤异种移植物的小鼠
	Dosages	12 mg/kg
	Administration	i.p.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
临床试验信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT00736372	Completed	Metastatic Cancer\|Advanced Cancer	Cascadian Therapeutics Inc.\|Seagen Inc.	June 2008	Phase 1
NCT00417287	Terminated	Pancreatic Neoplasms	Cascadian Therapeutics Inc.\|National Cancer Institute (NCI)\|Translational Genomics Research Institute\|Seagen Inc.	December 2006	Phase 2

参考文献
https://pubmed.ncbi.nlm.nih.gov/12657718/ https://pubmed.ncbi.nlm.nih.gov/21069338/ https://pubmed.ncbi.nlm.nih.gov/24172913/ https://pubmed.ncbi.nlm.nih.gov/26550453/ + 展开

参考文献

https://pubmed.ncbi.nlm.nih.gov/12657718/
https://pubmed.ncbi.nlm.nih.gov/21069338/
https://pubmed.ncbi.nlm.nih.gov/24172913/

https://pubmed.ncbi.nlm.nih.gov/26550453/

+ 展开

化学信息&溶解度

分子量	188.31	分子式	C₇H₁₂N₂S₂
CAS号	141400-58-0	SDF	Download PX-12 SDF
Smiles	CCC(C)SSC1=NC=CN1
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1年-80°C溶于溶剂
储存条件(自收到货起)	3年-20°C粉状	储备液保存和期限建议分装储备液，避免反复冻融！	1个月-20°C溶于溶剂

体外溶解度
批次：

DMSO : 38 mg/mL ( (201.79 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 38 mg/mL (201.79 mM)

Water : Insoluble

DMSO : 38 mg/mL ( (201.79 mM) ；DMSO吸湿会降低化合物溶解度，请使用新开封DMSO)

Ethanol : 38 mg/mL (201.79 mM)

Water : Insoluble

摩尔浓度计算器

体内溶解配方批次：现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂				动物体内配方计算器
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
澄清溶液	5%DMSO 1 Corn oil 该配方已经过Selleck实验室实测。如果上述溶解方案不能满足您的需求，可联系Selleck销售提供定制化测试。	2.400mg/ml (12.74mM)	以 1 mL 工作液为例，取50μL48mg/ml的澄清DMSO储备液加到950μL玉米油中，混合均匀。工作液请现配现用！
均匀悬浊液	CMC-NA	≥5mg/ml	以 1 mL 工作液为例，取 5 mg该产品加到 1 ml CMC-NA 溶液中，混合均匀，即可得工作液浓度为 5 mg/ml的均匀悬浊液。
澄清溶液	5%DMSO 1 30%PEG300 2 65%ddH2O 该配方已经过Selleck实验室实测。如果上述溶解方案不能满足您的需求，可联系Selleck销售提供定制化测试。	1.200mg/ml (6.37mM)	以 1 mL 工作液为例,取50 μL 24mg/ml的澄清DMSO储备液加到300 μL PEG300中,混合均匀使其澄清;向上述体系中加入650 μL ddH2O定容至1mL。工作液请现配现用!

实验计算

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×

稀释计算器分子量计算器

动物体内配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 μL 动物数量只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO + % + % Tween 80 + % ddH2O

%DMSO+ %

计算结果：

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH₂O，混匀澄清。

体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。

注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

* 必填项

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):